Skip to main content

The CAR Mechanics Group originated in 2004 and has sought to develop and translate novel CAR T-cell strategies for the treatment of patients with refractory solid tumours. We have developed several experimental CAR approaches in addition to ancillary technologies that enable improved CAR T-cell expansion and homing to sites of disease. The CAR Mechanics Group has advanced one candidate named T4 immunotherapy to Phase 1 clinical trial evaluation with funding from the Jon Moulton Charitable Foundation, Wellcome Trust and the Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust.

Our Partners

Car t mechanics logo

Group lead

Follow us